Internal Medicine, Endocrinology, Diabetes, & Metabolism · Farmington, CT
NPI
1487086625
Since 2013
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
263 Farmington Ave
Farmington, CT, 06030
Phone (860) 610-9814
Groups this clinician bills Medicare through
Medicare paid, 2024
$48K
495 services
Medicare patients, 2024
213
Average age 72
Drug cost, 2024
$3.6M
5,517 prescriptions
Company payments, 2025
$917
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Fatima Jalil was code 99214 (office e&m - established), 179 times for 131 patients. In total Fatima Jalil billed 495 services in 8 codes, and Medicare paid $48K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 179 | 131 | $91.01 | $16K |
| 99215 Office E&M - Established | Office | 152 | 96 | $133.79 | $20K |
| 95251 Test - Miscellaneous | Office | 90 | 52 | $25.93 | $2,334 |
| 99204 Office E&M - New | Office | 46 | 46 | $134.88 | $6,204 |
| 95250 Test - Miscellaneous | Office | 21 | 20 | $120.24 | $2,525 |
By year: 2022 $33K for 462 services; 2023 $38K for 486 services; 2024 $48K for 495 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 85 | 58 | $3.18 | $270 |
| 83036 Blood Count | 18 | 18 | $9.52 | $171 |
Medicare prescription drug claims, 2024
In 2024, the drug Fatima Jalil prescribed most often to Medicare patients was Ozempic (Semaglutide), with 720 prescriptions and refills. In total Fatima Jalil wrote 5,517 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 720 | 1,142 | 150 | $1.1M |
| Levothyroxine Sodium Generic | 439 | 1,215 | 117 | $3,809 |
| Jardiance Empagliflozin | 389 | 847 | 107 | $510K |
| Metformin Hcl Generic | 379 | 990 | 109 | $2,415 |
| Mounjaro Tirzepatide | 368 | 469 | 65 | $502K |
| Tresiba Flextouch U-100 Insulin Degludec | 254 | 638 | 83 | $196K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 202 | 445 | 52 | $32K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 135 | 349 | 61 | $17K |
| Farxiga Dapagliflozin Propanediol | 134 | 250 | 33 | $141K |
| Tresiba Flextouch U-200 Insulin Degludec | 105 | 203 | 30 | $102K |
| Synthroid Levothyroxine Sodium | 103 | 245 | 24 | $9,544 |
| Novolog Flexpen Insulin Aspart | 102 | 173 | 31 | $28K |
| Humalog Kwikpen U-100 Insulin Lispro | 99 | 194 | 33 | $29K |
| Metformin Hcl Er Metformin Hcl | 99 | 262 | 32 | $1,365 |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 96 | 152 | 35 | $28K |
Brand drugs: 3,449 claims; generic drugs: 1,578 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Fatima Jalil $917 ($917 in general payments such as food, travel and fees) from 7 companies. The largest payer was Novo Nordisk Inc with $334.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.